Biopharma AI
By
Can Catalio Capital’s $400 Million AI-Driven Life Sciences Fund Ignite a New Era of Biomedical Innovation Despite a Slow VC Market?
Key Takeaways Resilience in a Cooling VC ClimateCatalio Capital Management has successfully closed its fourth Nexus Fund at…
Is Portal Biotech’s $35M Series A Set to Redefine Proteomics With the World’s First AI-Powered Full-Length Single-Molecule Protein Sequencer?
Key Takeaways Transforming Protein Sequencing With AI and Nanopore InnovationPortal Biotech, a London-based pioneer in proteomics, is aiming…
How Is XtalPi’s Expanded Collaboration With Pfizer Set to Transform AI-Driven Small Molecule Drug Discovery?
Key Takeaways Empowering Next-Gen AI Platforms for Predictive Drug DiscoveryXtalPi and Pfizer have extended their strategic partnership to…
Is AI-Engineered HMBD-002 the Next Big Immunotherapy? Hummingbird Bioscience Signs $290M Global Licensing Deal with Percheron Therapeutics
Key Highlights Strategic Global Licensing Deal Hummingbird Bioscience has signed a worldwide licensing agreement with Percheron Therapeutics for…
Can Cedars-Sinai’s CS Connect Revolutionize Virtual Care? 42,000 Patients Served, AI Outperforms Doctors in 77% of Cases, K Health Partnership Sets New Standard
Key Takeaways: AI helping doctors focus on care, not paperworkCedars-Sinai launched CS Connect to improve access to care…
Can Novo Nordisk and Fangzhou’s AI-Powered Partnership Reshape Chronic Disease Care in China’s Digital Health Boom?
Key Insights: Revolutionizing Chronic Disease ManagementChina faces one of the world’s highest burdens of chronic diseases, particularly diabetes…
